The severity of ALL is generally estimated based on various prognostic factors such as Patient’s age, WBC count, chromosomal mutations, CNS involvement, and response to induction therapy, along with other factors. With the progress in understanding about the disease and genetic abnormalities involved, immunophenotypic/cytogenetic characterization has become an important parameter for selecting an appropriate treatment approach. Presence of Philadelphia chromosome predicts a poor disease outlook. Patient’s age and performance status is another most important parameter for the selection of appropriate treatment. Based on the age at ALL diagnosis, the patient population is generally divided into 2 groups: adolescent and young adults (AYA) patients and Adult patients. Young patients generally have a better outcome. The following table describes major ALL risk groups and associated characteristics
|Ph+ ALL in AYA patients||Patients with age 15 to 39 years and are positive for Philadelphia chromosomal abnormality|
|Ph+ ALL in Adult patients||Patients with age >/=40 years and who are positive for Philadelphia chromosomal abnormality|
|Ph- ALL in AYA patients||Patients with age 15 to 39 years and are negative for Philadelphia chromosomal abnormality|
|Ph- ALL in Adult patients||Patients with age >/=40 years and who are positive for Philadelphia chromosomal abnormality|
Join our community of fighters and survivors, motivate and uplift each other to fight cancer together.